IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2023
Aggregated presentation by day and by market
|
Name of issuer | Identification code of issuer (Legal Entity Identifier) |
Day of transaction |
Identification code of financial instrument | Aggregated daily volume (in number of shares) |
Daily weighted average price of the purchased shares * |
Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/06/2023 | FR0010259150 | 284 | 111,21 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/06/2023 | FR0010259150 | 690 | 111,19 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/06/2023 | FR0010259150 | 24 | 111,26 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/06/2023 | FR0010259150 | 2 979 | 110,74 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/06/2023 | FR0010259150 | 712 | 110,99 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/06/2023 | FR0010259150 | 549 | 110,94 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/06/2023 | FR0010259150 | 458 | 111,01 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/06/2023 | FR0010259150 | 3 681 | 110,81 | XPAR |
| * Two-digit rounding after the decimal | TOTAL | 9 377 | 110,86 | |||
Attachment
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen nominates Peter Guenter to its Board of Directors
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2025 12 31
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital